DK3518933T3 - Fremgangsmåder til behandling af uterusfibromer og endometriose - Google Patents

Fremgangsmåder til behandling af uterusfibromer og endometriose Download PDF

Info

Publication number
DK3518933T3
DK3518933T3 DK17823018.1T DK17823018T DK3518933T3 DK 3518933 T3 DK3518933 T3 DK 3518933T3 DK 17823018 T DK17823018 T DK 17823018T DK 3518933 T3 DK3518933 T3 DK 3518933T3
Authority
DK
Denmark
Prior art keywords
fibromes
endometriosis
uterus
procedures
treatment
Prior art date
Application number
DK17823018.1T
Other languages
English (en)
Other versions
DK3518933T4 (da
Inventor
Jr Paul N Mudd
Susan Wollowitz
Mark Hibberd
Vijaykumar Reddy Rajasekhar
Lynn Seely
Mayukh Vasant Sukhatme
Masataka Tanimoto
Brendan Mark Johnson
Original Assignee
Myovant Sciences Gmbh
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3518933(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myovant Sciences Gmbh, Takeda Pharmaceuticals Co filed Critical Myovant Sciences Gmbh
Application granted granted Critical
Publication of DK3518933T3 publication Critical patent/DK3518933T3/da
Publication of DK3518933T4 publication Critical patent/DK3518933T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
DK17823018.1T 2016-09-30 2017-09-29 Fremgangsmåder til behandling af uterusfibromer og endometriose DK3518933T4 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662402150P 2016-09-30 2016-09-30
US201662402055P 2016-09-30 2016-09-30
US201662402034P 2016-09-30 2016-09-30
US201762492839P 2017-05-01 2017-05-01
US201762528409P 2017-07-03 2017-07-03
PCT/EP2017/074907 WO2018060501A2 (en) 2016-09-30 2017-09-29 Methods of treating uterine fibroids and endometriosis

Publications (2)

Publication Number Publication Date
DK3518933T3 true DK3518933T3 (da) 2022-05-30
DK3518933T4 DK3518933T4 (da) 2025-04-22

Family

ID=60915460

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17823018.1T DK3518933T4 (da) 2016-09-30 2017-09-29 Fremgangsmåder til behandling af uterusfibromer og endometriose

Country Status (24)

Country Link
US (4) US11033551B2 (da)
EP (2) EP3518933B2 (da)
JP (1) JP7043503B2 (da)
CN (1) CN110312512B (da)
AU (2) AU2017336363B2 (da)
BR (1) BR112019006227A2 (da)
CA (1) CA3038879A1 (da)
CY (1) CY1125254T1 (da)
DK (1) DK3518933T4 (da)
ES (2) ES2912929T5 (da)
FI (1) FI3518933T4 (da)
HR (1) HRP20220708T4 (da)
HU (2) HUE059101T2 (da)
IL (2) IL300580B2 (da)
LT (1) LT3518933T (da)
MD (1) MD3518933T4 (da)
MX (1) MX2019003726A (da)
NZ (1) NZ752916A (da)
PL (2) PL4094766T3 (da)
PT (1) PT3518933T (da)
RS (1) RS63300B2 (da)
SI (1) SI3518933T2 (da)
SM (1) SMT202200254T1 (da)
WO (1) WO2018060501A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
CN110248661A (zh) 2016-09-30 2019-09-17 梦欧文科学有限责任公司 前列腺癌的治疗
SG11201911599XA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
SG11201911598WA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
AU2018419533A1 (en) * 2018-04-19 2020-11-12 Abbvie Inc. Methods of treating heavy menstrual bleeding
CA3117092A1 (en) * 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
RU2711658C1 (ru) * 2019-04-16 2020-01-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения наружного генитального эндометриоза
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
AU2020325655B2 (en) * 2019-08-08 2025-09-11 Kissei Pharmaceutical Co., Ltd. Compositions and methods for the treatment of estrogen-dependent disorders
EP4041738A1 (en) * 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
JP2022551316A (ja) * 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
EP4107525A4 (en) * 2020-02-19 2024-08-14 Aspira Women's Health Inc. Compositions for endometriosis assessment having improved specificity
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN117069735A (zh) * 2022-05-10 2023-11-17 北京海美源医药科技有限公司 一种高效合成瑞卢戈利的方法和其应用
WO2024015934A2 (en) * 2022-07-13 2024-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of diagnostic screening and early detection of adenomyosis
TW202428262A (zh) * 2022-11-09 2024-07-16 美商坦帕斯醫療公司 三唑酮化合物及其用途
WO2025106820A1 (en) * 2023-11-16 2025-05-22 University Of South Florida Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US402150A (en) 1889-04-30 Broadcast seed-sower
US402055A (en) 1889-04-23 Water-motor
US528409A (en) 1894-10-30 Denis ahern
US402034A (en) 1889-04-23 Dumping-wagon
US492839A (en) 1893-03-07 Key for brake-shoes
FR2512732A1 (fr) 1981-09-14 1983-03-18 Raffinage Cie Francaise Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
ECSP961635A (es) 1996-01-11 1997-06-27 Desprendimiento controlado de esteroides del recubrimiento de azucar
ECSP971998A (es) 1997-01-15 1998-04-07 Desprendimiento controlado de esteroides del recubrimiento de azucar
DE19815060A1 (de) 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
KR20030005205A (ko) 2000-02-29 2003-01-17 다케다 야쿠힌 고교 가부시키가이샤 티에노피리미딘 유도체의 제조 방법
US7569570B2 (en) 2002-01-30 2009-08-04 Takeda Pharmaceutical Company Limited Thienopyrimidines, process for preparing the same and use thereof
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
AU2004257639B2 (en) 2003-07-07 2011-01-06 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
KR20080041662A (ko) 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
EP2155194B1 (en) 2007-04-06 2015-01-21 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
EP2329823A4 (en) 2008-09-03 2013-04-03 Takeda Pharmaceutical PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA026675B1 (ru) 2010-06-16 2017-05-31 Эндорешерш, Инк. Способы лечения или предотвращения эстрогензависимых заболеваний
JP2012077020A (ja) 2010-09-30 2012-04-19 Mochida Pharmaceut Co Ltd ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
PL2900675T3 (pl) 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
CA2978223A1 (en) 2015-02-26 2016-09-01 Takeda Pharmaceutical Company Limited Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
US9949974B2 (en) 2015-09-01 2018-04-24 Abbvie Inc. Methods of adminstering elagolix
CN110248661A (zh) 2016-09-30 2019-09-17 梦欧文科学有限责任公司 前列腺癌的治疗
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
SG11201911598WA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
EP4041738A1 (en) 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Also Published As

Publication number Publication date
WO2018060501A3 (en) 2018-05-11
US11957684B2 (en) 2024-04-16
CA3038879A1 (en) 2018-04-05
BR112019006227A2 (pt) 2019-06-18
PT3518933T (pt) 2022-05-10
EP4094766B1 (en) 2025-04-02
JP2019529575A (ja) 2019-10-17
ES2912929T5 (en) 2025-05-09
SMT202200254T1 (it) 2022-07-21
PL3518933T5 (pl) 2025-05-05
US20190262346A1 (en) 2019-08-29
JP7043503B2 (ja) 2022-03-29
HRP20220708T1 (hr) 2022-07-22
US11033551B2 (en) 2021-06-15
RS63300B2 (sr) 2025-05-30
MD3518933T4 (ro) 2025-10-31
AU2022241582C1 (en) 2024-11-28
IL300580B1 (en) 2025-07-01
AU2017336363A1 (en) 2019-05-16
AU2022241582B2 (en) 2024-06-13
PL4094766T3 (pl) 2025-07-28
ES3018413T3 (es) 2025-05-16
EP3518933B2 (en) 2025-02-26
US20220370462A1 (en) 2022-11-24
SI3518933T1 (sl) 2022-06-30
AU2022241582A1 (en) 2022-10-27
AU2017336363B2 (en) 2022-08-04
CN110312512B (zh) 2023-05-09
MX2019003726A (es) 2019-09-26
EP4094766A1 (en) 2022-11-30
IL300580A (en) 2023-04-01
PL3518933T3 (pl) 2022-06-20
WO2018060501A2 (en) 2018-04-05
DK3518933T4 (da) 2025-04-22
IL265700B1 (en) 2023-03-01
IL265700A (en) 2019-05-30
FI3518933T4 (fi) 2025-05-14
HUE072130T2 (hu) 2025-10-28
IL265700B2 (en) 2023-07-01
RS63300B1 (sr) 2022-07-29
MD3518933T2 (ro) 2022-07-31
HRP20220708T4 (hr) 2025-04-25
ES2912929T3 (es) 2022-05-30
US11793812B2 (en) 2023-10-24
SI3518933T2 (sl) 2025-05-30
US20240165118A1 (en) 2024-05-23
IL300580B2 (en) 2025-11-01
CY1125254T1 (el) 2024-02-16
EP3518933A2 (en) 2019-08-07
EP3518933B1 (en) 2022-03-16
HUE059101T2 (hu) 2022-10-28
NZ752916A (en) 2022-09-30
LT3518933T (lt) 2022-06-10
US20210401841A1 (en) 2021-12-30
CN110312512A (zh) 2019-10-08

Similar Documents

Publication Publication Date Title
DK3518933T3 (da) Fremgangsmåder til behandling af uterusfibromer og endometriose
DK3264955T3 (da) Blandeanordning og fremgangsmåde
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
DK3442580T3 (da) Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme
DK3402888T3 (da) Middel og fremgangsmåder til behandling af hbv
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
EP3217046C0 (en) ASSEMBLIES AND ASSOCIATED METHODS
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3319611T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3277270T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3436022T3 (da) Oxysteroler og fremgangsmåder til anvendelse heraf
DK3558280T3 (da) Forebyggelse og behandling af migræne
DK3096684T3 (da) Anordning og fremgangsmåde til måling af kropsegenskaber
DK3234098T3 (da) Anordning og fremgangsmåde til påvisning af plantepatogener
DK3692009T3 (da) Biocementationsfremgangsmåde og system
DK3194328T3 (da) Gelformpude og fremgangsmåde til fremstilling af samme
EP3703321A4 (en) CONFIGURATION PROCESS AND APPARATUS
DK3695103T3 (da) Anordning og fremgangsmåde til køling
DK3265641T3 (da) Stigørenhed og fremgangsmåde
EP3570230A4 (en) WORK ASSISTANCE DEVICE AND WORK ASSISTANCE PROCESS
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3265126T3 (da) Kombinationsformulering af tesofensin og metoprolol
DK3191103T3 (da) Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner